EU approves Takeda’s bowel drug Entyvio

New Drug Approvals

EU approves Takeda's bowel drug Entyvio

Hot on the heels of an approval in the US, regulators in Europe have now also given Takeda’s Entyvio (vedolizumab) the nod for two inflammatory bowel diseases. The European Commission has granted Marketing Authorisation for use of the gut-selective humanised monoclonal antibody to treat adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD).

Read more at:

View original post


Pharmaceutical Water: Uncertainty caused by the New Biocidal Products Regulation

Pharmaceutical Water: Uncertainty caused by the New Biocidal Products Regulation
Many pharmaceutical water facility operators are not aware of the Biocidal Product Regulation which came into force on 1st September 2013 which implies a product registration for ozone equipment.Read more here.





MOBILE-+91 9323115463
web link

Congratulations! Your presentation titled “Anthony Crasto Glenmark scientist, helping millions with websites” has just crossed MILLION views.
アンソニー     安东尼   Энтони    안토니     أنتوني
join my process development group on google
you can post articles and will be administered by me on the google group which is very popular across the world
LinkedIn group
blogs are



WHO publishes Draft on Process Validation

Dated April 2014 the WHO published a proposal for the revision of appendix 7 (non-sterile process validation) as a supplementary to the Guidelines on Good Manufacturing Practices. The reason given for the revision is compliance with actual GMP requirements. The following is an in-depth analysis.,8480,8550,8471,Z-VM_n.html

Europe’s May 2014 Products Recommended For Orphan Drug Designation

Orphan Druganaut Blog

The European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) held a meeting May 13 – 14, 2014. The EMA COMP May 2014 Meeting Report on the review of applications for orphan designation is published May 16.

At this meeting, there are 10 positive opinions recommending the following medicines for designation as orphan medicinal products. COMP’s opinions are then forwarded to the European Commission (EC). The EC will then decide whether to grant an orphan designation for the medicines in question. Public summaries of the opinions will be available on the EMA website following adoption of the respective decisions on orphan designation by the EC :

 Product NameSponsor CompanyIndication
1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropanecarboxamideVertex PharmaceuticalsCystic Fibrosis
Isavuconazonium sulfateFondazione TelethonStargardt’s Disease
Mixture of two adeno-associated viral vectors serotype 8 containing the 5’-half sequence of human MYO7A gene and the 3’-half sequence of human MYO7A geneFondazione TelethonUsher Syndrome
Adeno-associated viral vector…

View original post 106 more words

India business robust in terms of growth: Glenmark….videos

New Drug Approvals



India business robust in terms of growth: Glenmark on Q1…/news/video-india-business-robust…
Aug 2, 2013

NDTV Profit News Video Clip on India business robust in terms of growth: … chairman and managing director …

View original post

Astellas’ Dificlir (fidaxomicin) could save NHS thousands of pounds

New Drug Approvals



873857-62-6 3-(((6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-β-D-mannopyranosyl)oxy)-methyl)-12(R)-[(6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-β-D-lyxo-hexopyranosyl)oxy]-11(S)-ethyl-8(S)-hydroxy-18(S)-(1(R)-hydroxyethyl)-9,13,15-trimethyloxacyclooctadeca-3,5,9,13,15-pentaene-2-one

C52H74Cl2O18   Molecular Weight: 1058.03916 

US FDA:link         Launched – 2011   Clostridium difficile-associated diarrhea


Astellas' Dificlir could save NHS thousands of poundsUsing Astellas’ Dificlir (fidaxomicin) as a first-line treatment for clostridium difficile infection (CDI) is not only clinically effective but could also save the National Health Service thousands of pounds compared to the standard of care, according to data from a late-stage study

Read more at:

Fidaxomicin (trade names DificidDificlir, and previously OPT-80 and PAR-101) is the first in a new class of narrow spectrummacrocyclic antibiotic drugs.[2] It is a fermentation product obtained from the actinomycete Dactylosporangium aurantiacum subspecies hamdenesis.[3][4] Fidaxomicin is non-systemic, meaning it is minimally…

View original post 1,174 more words

For National Women’s Health Week, FDA Resources Help Women Make Informed Health Choices

New Drug Approvals

For National Women’s Health Week, FDA Resources Help Women Make Informed Health Choices

By: Marsha B. Henderson, M.C.R.P. “Ask your mother.” In households throughout the country, women often make decisions about foods and medical products for themselves and their loved ones. As we celebrate National Women’s Health Week (May 11-17), I want to … Continue reading →

View original post

EMA: new guidance for pharma on early HTA dialogue

EMA: new guidance for pharma on early HTA dialogue

The European Medicines Agency (EMA) has published draft best-practice guidance for industry on parallel scientific advice with health technology assessment (HTA) agencies, aimed at facilitating early dialogue between regulators, HTA bodies and drug developers.

GDP Question: When to use Mean Kinetic Temperature Calculation (MKT)?

GDP Question: When to use Mean Kinetic Temperature Calculation (MKT)?
The British Medicines Authority MHRA is performing GMP and GDP Inspections on a risk based strategy. Based on the experience the MHRA answers frequent asked questions. One very interesting Q&A refers to Mean Kinetic Temperature Calculations (MKT). Read more about MKT here

Read more about MKT here


EMA publishes Guideline Draft on Validation of biotechnology-derived Products

For the EMA, it was necessary to develop an independent guideline on the topic as – despite the existence of harmonised ICH documents – specific aspects of the validation of biotechnology-derived products have been missing. A draft is now available.

A draft is now available.

EMA publishes Guideline Draft on Validation of biotechnology-derived Products



Top 15 Drug Launch Superstars

Jayan Rappai

Top 15 Drug Launch Superstars

A year ago, FiercePharma published a list of drugs that missed when stepping on the up escalator. A heel got caught, or a sleeve. Bystanders hit the emergency stop button. For whatever reason, escalate they did not. We called it “Top 10 Drug Launch Disasters.” It’s still one of our most popular special reports.

This year, we wanted to take a more positive approach. So, herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge–one we weren’t exactly expecting, based on previous experience. Turns out, as tough as it may be to identify disasters before they happen, it’s not so difficult after the fact. To go back to the escalator analogy, it’s like trying…

View original post 687 more words